Abstract

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as 'dioxin'. AHR influences the major stages of tumorigenesis-initiation, promotion, progression and metastasis-and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.

Original languageEnglish (US)
Pages (from-to)801-814
Number of pages14
JournalNature Reviews Cancer
Volume14
Issue number12
DOIs
StatePublished - Nov 24 2014

Fingerprint

Aryl Hydrocarbon Receptors
Ligands
Neoplasms
Carcinogenesis
Dioxins
Adaptive Immunity
Tumor Cell Line
Innate Immunity
Carcinogens
Rodentia
Transcription Factors
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{1e5fe9b7f05e4e84b6ec32349e14ff1f,
title = "Aryl hydrocarbon receptor ligands in cancer: Friend and foe",
abstract = "The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as 'dioxin'. AHR influences the major stages of tumorigenesis-initiation, promotion, progression and metastasis-and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.",
author = "Murray, {Iain Alexander} and Patterson, {Andrew David} and Perdew, {Gary H.}",
year = "2014",
month = "11",
day = "24",
doi = "10.1038/nrc3846",
language = "English (US)",
volume = "14",
pages = "801--814",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "12",

}

Aryl hydrocarbon receptor ligands in cancer : Friend and foe. / Murray, Iain Alexander; Patterson, Andrew David; Perdew, Gary H.

In: Nature Reviews Cancer, Vol. 14, No. 12, 24.11.2014, p. 801-814.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aryl hydrocarbon receptor ligands in cancer

T2 - Friend and foe

AU - Murray, Iain Alexander

AU - Patterson, Andrew David

AU - Perdew, Gary H.

PY - 2014/11/24

Y1 - 2014/11/24

N2 - The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as 'dioxin'. AHR influences the major stages of tumorigenesis-initiation, promotion, progression and metastasis-and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.

AB - The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that is best known for mediating the toxicity and tumour-promoting properties of the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin, commonly referred to as 'dioxin'. AHR influences the major stages of tumorigenesis-initiation, promotion, progression and metastasis-and physiologically relevant AHR ligands are often formed during disease states or during heightened innate and adaptive immune responses. Interestingly, ligand specificity and affinity vary between rodents and humans. Studies of aggressive tumours and tumour cell lines show increased levels of AHR and constitutive localization of this receptor in the nucleus. This suggests that the AHR is chronically activated in tumours, thus facilitating tumour progression. This Review discusses the role of AHR in tumorigenesis and the potential for therapeutic modulation of its activity in tumours.

UR - http://www.scopus.com/inward/record.url?scp=84922481111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922481111&partnerID=8YFLogxK

U2 - 10.1038/nrc3846

DO - 10.1038/nrc3846

M3 - Review article

C2 - 25568920

AN - SCOPUS:84922481111

VL - 14

SP - 801

EP - 814

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 12

ER -